Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells

Molecular Carcinogenesis

Volumn 26, Issue 1, 1999, Pages 53-61

  Lin, Kwang Huei ^a   Shieh, Hsing Ying ^a   Chen, Shen Liang ^a   Hsu, Hai Chu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Mutation; Receptor; Thyroid hormone

Indexed keywords

CELL NUCLEUS RECEPTOR; THYROID HORMONE; THYROID HORMONE RECEPTOR;

ARTICLE; CARCINOGENESIS; DNA BINDING; DNA SEQUENCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTORS, THYROID HORMONE;

EID: 0032850236     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z     Document Type: Article

References (37)

1. Saeter G, Seglen PO. Cell biology of hepatocarcinogenesis. Crit Rev Oncog 1990;1:437-466.
2. Francavilla A, Azzarone A, Starzl TE, Giangaspero A, Panella C. Hormones, growth factors and oncogenes in the evaluation of risk of hepatocellular carcinomas. European Journal of Cancer Prevention 1992;Suppl 3:55-58.
3. Schirmacher P, Rogler CE, Dienes HP. Current pathogenetic and molecular concepts in viral liver carcinogenesis. Virchows Arch 1993;63:71-89.
4. Oppenheimer JH, Samuels HH. Molecular basis of thyroid hormone action. New York: Academic Press; 1983. p. 64-199.
5. Cheng S.-y. New insights into the structure and function of the thyroid hormone receptor. J Biomed Sci 1995;2: 77-89.
6. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and compressors. Mol Endocrinol 1996;10:1167-1177.
7. Yap N, Yu C-L, Cheng S -y. Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc Natl Acad Sci USA 1996;93: 4273-4277.
8. Bhat MK, Yu CI, Yap N, Zhan Q, Hayashi Y, Swth P, Cheng S-y. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways. J Biol Chem 1997; 272:28989-28993.
9. Yen PM, Ikeda M, Brubaker JH, Forgione M, Sugawara A, Chin WW. Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA. J Biol Chem 1994;269:903-909.
10. Privalsky ML. v-erb A, nuclear hormone receptors, and oncogenesis. Biochem Biophys Acta 1992;1114:51-62.
11. Casini T, Graf T. Bicistronic retroviral vector reveals capacity of v-erbA to induce erythroleukemia and to co-operate with v-myb. Oncogene 1995;11:1019-1026.
12. Barlow C, Meister B, Lardelli M, Lendahl U, Vennstrom B. Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J 1994;13:4241-4250.
13. Lin KH, Zhu X-G, Shieh, H-y, et al. Identification of naturally occurring dominant negative mutants of thyroid hormone α1 and β1 receptors in a human hepatocellular carcinoma cell line. Endocrinology 1996;137:4073-4081.
14. Lin KH, Zhu XG, Hsu HC, et al. Dominant negative activity of mutant thyroid hormone α1 receptors from patients with hepatocellular carcinoma. Endocrinology 1997;138: 5308-5315.
15. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. Science 1985;230:1242-1246.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
17. Cook CB, Kakucska I, Lechan RM, Koening RJ. Expression of thyroid hormone receptor beta 2 in rat hypothalamus. Endocrinology 1992;130:1077-1079.
18. Lin KH, Brennan M, Lindahl R. Expression of tumor associated aldehyde dehydrogenase gene in rat hepatoma cell lines. Cancer Res 1988;48:7009-7012.
19. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
20. Bhat MK, McPhie P, Cheng SY. Interaction of thyroid hormone nuclear receptor with antibody: Characterization of the thyroid hormone binding site. Biochem Biophys Res Commun 1995;210:464-471.
21. Zhu XG, Yu CL, McPhie P, Wong R, Cheng SY. Understanding the molecular mechanism of dominant negative action of mutant thyroid hormone beta 1-receptors: The important role of the wild-type/mutant receptor heterodimer. Endocrinology 1996;137:712-721.
22. Lin KH, Fukuda T, Cheng SY. Hormone and DNA binding activity of a purified thyroid hormone nuclear receptor expressed in Escherichia coli. J Biol Chem 1990;265: 5161-5165.
23. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993;14: 348-399.
24. Usala SJ. New developments in clinical and genetic aspects of thyroid hormone resistance syndromes. Endocrinologist 1995;5:68-76.
25. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone: The NIH prospective study. Ann Intern Med 1995;123: 572-583.
26. Dayton AI, Selden JR, Laws G, et al. A human c-erbA oncogene homologue is closely proximal to the chromosome 17 breakpoint in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1984;81:4495-4499.
27. Nohno T, Kasai Y, Saito T. Novel cDNA sequence possibly generated by alternative splicing of a mouse glucocorticoid receptor gene transcript from Shionogi carcinoma 115. Nucleic Adds Res 1989;17:445.
28. Dobrovic A, Houle B, Belouchi A, Bradley W. erbA-related sequence coding for DNA-binding hormone receptor localized to chromosome 3p21-3p25 and deleted in small cell lung carcinoma. Cancer Res 1988;48:682-685.
29. Ali I, Lidereau R, Callahan R. Presence of two members of c-erbA receptor gene family in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma. J Natl Cancer Inst 1989;81: 1815-1820.
30. Markowitz S, Haut M, Stellato T, Gerbic C, Molkentin K. Expression of the erbAβ class of thyroid hormone receptors is selectively lost in human colon carcinoma. J Clin Invest 1989;84:1683-1687.
31. Dejean A, Bougueleret L, Grzeschik K, Tiolais P. Hepatitis B virus DNA integration in a sequence homologous to v-erbA and steroid receptor genes in a hepatocellular carcinoma. Nature 1986;322:70-72.
32. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: Many actors in search of a plot. Cell 1995;83: 851-857.
33. Yoh SM, Chatterjee VK, Privalsky ML. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol 1997;11:470-480.
34. Liu Y, Takeshita A, Misiti S, Chin WW, Yen PM. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors. Endocrinology 1998;139:4197-4204.
35. Maxwell SA, Roth JA. Posttranslational regulation of p53 tumor suppressor protein function. Crit Rev Oncog 1994; 5:23-57.
36. Perez P, Schonthal A, Aranda A. Repression of c-fos gene expression by thyroid hormone and retinoic acid receptors. J Biol Chem 1993;268:23538-23543.
37. Wang LD, Hoeltzel M, Butler K, Hare B, Todisco A, Wang M, Del Valle J. Activation of the human histamine H2 receptor is linked to cell proliferation and c-fos gene transcription. J Physiol 1997;273:2037-2045.